otilimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
otilimab

GtoPdb Ligand ID: 11132

Synonyms: GSK-3196165 | GSK3196165 | MOR-103 | MOR103

Compound class: Antibody

Comment: Otilimab (MOR103, GSK3196165) is a clinical stage fully human IgG1λ antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2). It is being investigated as a therapeutic for inflammatory diseases. MOR103 was developed using MorphoSys' HuCAL® technology, and has been fully out-licensed otilimab to GSK. MOR103 is claimed as MOR-04357 in patent WO2006122797A2 (by BLAST peptide sequence matching) [5].

Immunopharmacology Comments
GM-CSF is a component of the natural immune response and inflammatory cascade. It has also been identified as an inflammatory mediator in autoimmune disorders, where it drives the increased production of pro-inflammatory cytokines, chemokines and proteases that underlie disease pathology. GM-CSF is therefore considered to be a target for therapies that would offer broad spectrum anti-inflammatory activity [4].

Immunopharmacology Comments

GM-CSF is a component of the natural immune response and inflammatory cascade. It has also been identified as an inflammatory mediator in autoimmune disorders, where it drives the increased production of pro-inflammatory cytokines, chemokines and proteases that underlie disease pathology. GM-CSF is therefore considered to be a target for therapies that would offer broad spectrum anti-inflammatory activity [4].